Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience

Giulio Francolini; Riccardo Campi; Vanessa Di Cataldo; Beatrice Detti; Mauro Loi; Luca Triggiani; Salvatore La Mattina; Paolo Borghetti; Stefano Maria Magrini; Luca Nicosia; Filippo Alongi; Paolo Ghirardelli; Vittorio Vavassori; Andrea Gaetano Allegra; Michele Aquilano; Erika Scoccimarro; Anna Peruzzi; Pierpaolo Pastina; Luca Visani; Isacco Desideri; Sergio Serni; Icro Meattini; Lorenzo Livi

doi:10.1007/s12094-022-02844-5

Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience

Clin Transl Oncol. 2022 Oct;24(10):2039-2043. doi: 10.1007/s12094-022-02844-5. Epub 2022 Jun 23.

Authors

Giulio Francolini¹, Riccardo Campi², Vanessa Di Cataldo³, Beatrice Detti⁴, Mauro Loi¹, Luca Triggiani⁵, Salvatore La Mattina⁵, Paolo Borghetti⁵, Stefano Maria Magrini⁵, Luca Nicosia⁶, Filippo Alongi⁶, Paolo Ghirardelli⁷, Vittorio Vavassori⁷, Andrea Gaetano Allegra⁸, Michele Aquilano⁸, Erika Scoccimarro⁸, Anna Peruzzi⁸, Pierpaolo Pastina⁹, Luca Visani³, Isacco Desideri⁸, Sergio Serni¹⁰, Icro Meattini⁸, Lorenzo Livi⁸

Affiliations

¹ Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
² Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy.
³ Radiotherapy Department, Istituto Fiorentino di Cura e Assistenza, Florence, Italy.
⁴ Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy. beatrice.detti@aouc.unifi.it.
⁵ Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
⁶ Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy.
⁷ Department of Radiotherapy, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
⁸ Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
⁹ Section of Radiation Oncology, Medical School, University of Siena, Siena, Italy.
¹⁰ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Abstract

Purpose: To explore the benefit yielded by radiotherapy (RT), we report a series of metastatic renal cell carcinoma (RCC) patients treated with concomitant RT plus Nivolumab.

Methods/patients: Patients undergoing Nivolumab treatment plus concomitant RT (ablative or palliative) were included. RT was defined Ablative if >5 Gy/fraction were delivered.

Results: Ablative RT intent was the only independent predictor of both progression free and overall survival (HR 3.51, 95% CI 1.6-7.5, p = 0.0012 and HR 2.8, 95% CI 0.99-8.07, p = 0.05, respectively).

Conclusion: Ablative RT may improve oncologic outcomes in selected patients with metastatic RCC treated with Nivolumab as compared to palliative RT.

Keywords: Metastatic renal cell carcinoma; SBRT; Stereotactic ablative radiotherapy.

Publication types

Multicenter Study

MeSH terms

Carcinoma, Renal Cell*
Humans
Immune Checkpoint Inhibitors
Kidney Neoplasms*
Nivolumab
Radiosurgery*

Substances

Immune Checkpoint Inhibitors
Nivolumab